<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866108</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-013-FLAG-C104</org_study_id>
    <nct_id>NCT04866108</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy</brief_title>
  <official_title>A Single Center, Open-labeled, Single Arm Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-labeled, single arm phase II study aimed to investigate the&#xD;
      efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for&#xD;
      advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, this phase II study aimed to&#xD;
      investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line&#xD;
      treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable&#xD;
      for intravenous chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From Baseline to primary completion date, about 3 years</time_frame>
    <description>ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) version. 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From Baseline to primary completion date, about 3 years</time_frame>
    <description>OS is determined from the date of treatment to death from any cause or the last follow-up date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From Baseline to primary completion date, about 3 years</time_frame>
    <description>PFS is determined from the date of treatment to PD or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From Baseline to primary completion date, about 3 years</time_frame>
    <description>DCR according to Response Evaluation Criteria in Solid Tumors (RECIST) version. 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>From Baseline to primary completion date, about 3 years</time_frame>
    <description>Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>From Baseline to primary completion date, about 3 years</time_frame>
    <description>Quality of life is assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30. It will be evaluated at Screening, Tumor Assessment Visit and End of Treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Unresectable Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fruquintinib, 4mg/d, qd po, 2 weeks on, 1 week off; Capecitabine: 825mg/m2, bid po, 2 weeks on, 1 week off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fruquintinib plus capecitabine</intervention_name>
    <description>oral fruquintinib plus capecitabine</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years old at the time of signing the informed consent;&#xD;
&#xD;
          2. Histologically or cytologically confirmed unresectable metastatic colorectal cancer;&#xD;
&#xD;
          3. Haven't received systematic therapy after diagnosis of metastatic colorectal cancer;&#xD;
&#xD;
          4. Intolerable to standard treatment of oxaliplatin- or irinotecan-based intravenous&#xD;
             combination therapy;&#xD;
&#xD;
          5. At least one measurable lesion(s);&#xD;
&#xD;
          6. ECOG PS 0-2;&#xD;
&#xD;
          7. Life expectancy≥3 months;&#xD;
&#xD;
          8. Adequate organ and bone marrow functions;&#xD;
&#xD;
          9. Women of childbearing age must have a negative pregnancy test within the first day of&#xD;
             the study, and contraceptive methods should be taken during the study until 6 months&#xD;
             after the last administration;&#xD;
&#xD;
         10. Willingness and able to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with VEGFR inhibition;&#xD;
&#xD;
          2. Participating in other drug clinical trials within 4 weeks before recruited;&#xD;
&#xD;
          3. Have received other systemic anti-tumor therapies within 4 weeks before recruited;&#xD;
&#xD;
          4. Non-controlled hypertension after monotherapy, that is, systolic blood pressure &gt;&#xD;
             140mmHg or diastolic blood pressure &gt; 90mmHg;&#xD;
&#xD;
          5. Proteinuria ≥ 2+ (1.0g/24hr);&#xD;
&#xD;
          6. Clinically significant electrolyte abnormality;&#xD;
&#xD;
          7. Clinically significant cardiovascular diseases;&#xD;
&#xD;
          8. Thromboembolism or arteriovenous events occurred 6 months before recruited;&#xD;
&#xD;
          9. ≥grade 3 bleeding events 4 weeks before recruited;&#xD;
&#xD;
         10. Evidence of CNS metastasis;&#xD;
&#xD;
         11. Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in&#xD;
             GI;&#xD;
&#xD;
         12. Active, symptomatic interstitial lung disease causing dyspnea (≥ grade 2 dyspnea),&#xD;
             pleural effusion or ascites;&#xD;
&#xD;
         13. History of organ transplantation;&#xD;
&#xD;
         14. APTT &gt;1.5×ULN or INR&gt;1.5;&#xD;
&#xD;
         15. History of HIV infection or active hepatitis B / C;&#xD;
&#xD;
         16. Allergic to fruquintinib and / or capecitabine;&#xD;
&#xD;
         17. Pregnant or lactating women;&#xD;
&#xD;
         18. Clinically detectable secondary primary malignancies at the time of enrollment&#xD;
             (excluding fully treated basal cell carcinoma of the skin or carcinoma in situ of the&#xD;
             cervix);&#xD;
&#xD;
         19. Patients who are not suitable for the study judged by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhigang Bai</last_name>
    <phone>+86-010-63138712</phone>
    <email>baizhigang@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Bai Zhigang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

